XTRA:HPHABiotechs
Heidelberg Pharma (XTRA:HPHA) FY 2025 Loss Deepens To €0.91 EPS Challenges Growth Narrative
Heidelberg Pharma FY 2025 earnings snapshot
Heidelberg Pharma (XTRA:HPHA) has reported its FY 2025 results, with fourth quarter revenue of €5.5 million and a basic EPS loss of €0.46, while the latest trailing twelve month figures show total revenue of €6.9 million and a basic EPS loss of €0.91. Over recent periods, revenue has ranged from €0.05 million to €5.5 million per quarter, with quarterly basic EPS losses between €0.13 and €0.46. The latest figures keep the focus on how efficiently the...